Literature DB >> 15691842

The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.

Christine Yu1, Kathleen Markan, Karla A Temple, Dianne Deplewski, Matthew J Brady, Ronald N Cohen.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is a central regulator of adipogenesis and recruits coactivator proteins in response to ligand. However, the role of another class of nuclear cofactors, the nuclear receptor corepressors, in modulating PPARgamma transcriptional activity is less clear. Such corepressors include the nuclear receptor corepressor (NCoR) and the silencing mediator of retinoid and thyroid hormone receptors (SMRT). Our data suggest that PPARgamma recruits SMRT and NCoR in the absence of ligand and that these corepressors are capable of down-regulating PPARgamma-mediated transcriptional activity. The addition of the PPARgamma ligand pioglitazone results in dissociation of the PPARgamma-corepressor complex. To define the role of SMRT and NCoR in PPARgamma action, 3T3-L1 cells deficient in SMRT or NCoR were generated by RNA interference. When these cells are exposed to differentiation media, they exhibit increased expression of adipocyte-specific genes and increased production of lipid droplets, as compared with control cells. These data suggest that the nuclear receptor corepressors decrease PPARgamma transcriptional activity and repress the adipogenic program in 3T3-L1 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15691842     DOI: 10.1074/jbc.M409468200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  108 in total

1.  The ubiquitin ligase Siah2 regulates PPARγ activity in adipocytes.

Authors:  Gail Kilroy; Heather Kirk-Ballard; Lauren E Carter; Z Elizabeth Floyd
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

2.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

3.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

Review 4.  A chromatin perspective of adipogenesis.

Authors:  Melina M Musri; Ramon Gomis; Marcelina Párrizas
Journal:  Organogenesis       Date:  2010 Jan-Mar       Impact factor: 2.500

Review 5.  Review: Epigenetic regulation of adipocyte differentiation and adipogenesis.

Authors:  Hong-xing Li; Lei Xiao; Cheng Wang; Jia-li Gao; Yong-gong Zhai
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

6.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

7.  Mice lacking PGC-1β in adipose tissues reveal a dissociation between mitochondrial dysfunction and insulin resistance.

Authors:  Natàlia Enguix; Rosario Pardo; Agustí González; Víctor M López; Rafael Simó; Anastasia Kralli; Josep A Villena
Journal:  Mol Metab       Date:  2013-06-05       Impact factor: 7.422

8.  Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT) regulates glucocorticoid action in adipocytes.

Authors:  Margo P Emont; Stelios Mantis; Jonathan H Kahn; Michael Landeche; Xuan Han; Robert M Sargis; Ronald N Cohen
Journal:  Mol Cell Endocrinol       Date:  2015-03-09       Impact factor: 4.102

9.  Nuclear translocation of MEK1 triggers a complex T cell response through the corepressor silencing mediator of retinoid and thyroid hormone receptor.

Authors:  Lei Guo; Chaoyu Chen; Qiaoling Liang; Mohammad Zunayet Karim; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

Review 10.  PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.

Authors:  Neville F Mistry; Sharon Cresci
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.